stoxline Quote Chart Rank Option Currency Glossary
  
Bone Biologics Corporation (BBLG)
2.13  0.06 (2.9%)    03-28 16:00
Open: 2.0411
High: 2.26
Volume: 20,948
  
Pre. Close: 2.07
Low: 2.02
Market Cap: 2(M)
Technical analysis
2024-03-28 4:49:57 PM
Short term     
Mid term     
Targets 6-month :  3.56 1-year :  4.3
Resists First :  3.05 Second :  3.69
Pivot price 2.3
Supports First :  2.01 Second :  1.68
MAs MA(5) :  2.14 MA(20) :  2.32
MA(100) :  3.49 MA(250) :  14.98
MACD MACD :  -0.3 Signal :  -0.3
%K %D K(14,3) :  6.6 D(3) :  9.7
RSI RSI(14): 39.2
52-week High :  86.87 Low :  2.01
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ BBLG ] has closed above bottom band by 21.8%. Bollinger Bands are 66.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.26 - 2.27 2.27 - 2.29
Low: 1.99 - 2.01 2.01 - 2.02
Close: 2.11 - 2.13 2.13 - 2.15
Company Description

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.

Headline News

Thu, 28 Mar 2024
Bone Biologics Co. (NASDAQ:BBLG) Short Interest Down 75.1% in March - Defense World

Tue, 26 Mar 2024
Bone Biologics (OTC:BBLG) Stock Price Down 1.3% - Defense World

Thu, 14 Mar 2024
Should You Buy Bone Biologics Corp (BBLG) Stock After it Is Up 2.99% in a Week? - InvestorsObserver

Wed, 06 Mar 2024
Bone Biologics Announces Closing of $2.0 Million Public Offering - OrthoSpineNews

Mon, 04 Mar 2024
Bone Biologics rises 5% on $2M equity offering (NASDAQ:BBLG) - Seeking Alpha

Fri, 01 Mar 2024
Bone Biologics Reports Progress With NB1 Clinical Program - OrthoSpineNews

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Medical - Devices
Shares Out 1 (M)
Shares Float 0 (M)
Held by Insiders 8.1 (%)
Held by Institutions 1.2 (%)
Shares Short 125 (K)
Shares Short P.Month 10 (K)
Stock Financials
EPS -34.01
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 5.44
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -96.4 %
Return on Equity (ttm) -202.2 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow -10 (M)
Levered Free Cash Flow -7 (M)
Stock Valuations
PE Ratio -0.07
PEG Ratio 0
Price to Book value 0.39
Price to Sales 0
Price to Cash Flow -0.2
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android